+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates



Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates



Cochrane Database of Systematic Reviews 2002(3): Cd003313



Exchange transfusion and phototherapy have traditionally been used to treat jaundice and avoid the associated neurological complications. Exchange transfusion is not without risk and intravenous immunoglobulin has been suggested as an alternative therapy for isoimmune haemolytic jaundice to reduce the need for exchange transfusion. To assess whether the use of intravenous immunoglobulin, in newborn infants with isoimmune haemolytic jaundice, is effective in reducing the need for exchange transfusion. The search strategy of the Cochrane Neonatal Review group was used. Searches were made of MEDLINE 1966-2002, EMBASE Drugs and Pharmacology 1990-2002, Cochrane Controlled Trials Register, The Cochrane Library, Issue 1, 2002, expert informants, review articles, cross references, and hand searching of abstracts and conference proceedings of the annual meetings of The Society for Pediatric Research 1990-2001 and The European Society for Paediatric Research 1990-2001. All randomised and quasi-randomised controlled trials of the use of intravenous immunoglobulin in the treatment of isoimmune haemolytic disease were considered. The standard methods of the Cochrane Collaboration and its Neonatal Review Group were used. Studies were assessed for inclusion and quality by two reviewers working independently, with the second reviewer blinded to trial author, institution and journal of publication. Data were extracted independently by the two reviewers. Any differences of opinion were discussed and a consensus reached. Investigators were contacted for additional or missing information. For categorical outcomes, the relative risk (RR), risk difference (RD) and the number needed to treat (NNT) were calculated. For continuous variables, the weighted mean difference (WMD) was calculated. Seven studies were identified. Three of these fulfilled the inclusion criteria and included a total of 189 infants. Term and preterm infants and infants with rhesus and ABO incompatibility were included. The use of exchange transfusion decreased significantly in the immunoglobulin treated group (typical RR 0.28, 95% CI 0.17, 0.47; typical RD -0.37, 95% CI -0.49, -0.26; NNT 2.7). The mean number of exchange transfusions per infant was also significantly lower in the immunoglobulin treated group (WMD -0.52, 95% CI -0.70, -0.35). None of the studies assessed long term outcomes. Although the results show a significant reduction in the need for exchange transfusion in those treated with intravenous immunoglobulin, the applicability of the results is limited. The number of studies and infants included is small and none of the three included studies was of high quality. The protocols of two of the studies mandated the use of early exchange transfusion, limiting the generalizability of the results. Further well designed studies are needed before routine use of intravenous immunoglobulin can be recommended for the treatment of isoimmune haemolytic jaundice.

(PDF emailed within 0-6 h: $19.90)

Accession: 046333274

Download citation: RISBibTeXText

PMID: 12137687

DOI: 10.1002/14651858.CD003313


Related references

Should intravenous immunoglobulin be used in infants with isoimmune haemolytic disease due to ABO incompatibility?. Journal of Paediatrics and Child Health 49(12): 1072-1078, 2014

Intravenous immunoglobulin in isoimmune haemolytic disease of newborn: an updated systematic review and meta-analysis. Archives of Disease in Childhood. Fetal and Neonatal Edition 99(4): F325-F331, 2014

Meta analysis of the effect of immunoglobulin infusion on neonatal isoimmune hemolytic disease caused by blood group incompatibility. Zhonghua Er Ke Za Zhi 48(9): 656-660, 2011

High dose intravenous immunoglobulin in haemolytic disease of neonates. Archives of Disease in Childhood. Fetal and Neonatal Edition 88(5): F444-5; Author Reply F445, 2003

Use of intravenous immunoglobulin in neonates with haemolytic disease and immune thrombocytopenia. Vojnosanitetski Pregled 70(11): 1029-1033, 2014

High-dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica 89(3): 371-372, 2000

Perforated appendicitis after intravenous immunoglobulin therapy in a term neonate with haemolytic jaundice. Journal of the College of Physicians and Surgeons--Pakistan 25(4): 296-298, 2015

High-dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica 88(2): 216-219, 1999

Serum protein immunoglobulin and haemolytic complement levels in the sera of buffalo neonates. Indian Journal of Animal Sciences 62(8): 728-731, 1992

Haemolytic anaemia as a complication to intravenous infusion of human immunoglobulin. Ugeskrift for Laeger 173(33): 1963-1964, 2011

Safety of intravenous immunoglobulin infusion in neonates at risk for sepsis. American Journal of Perinatology 7(4): 307-311, 1990

Isoimmune haemolytic icterus in neonatal calves as a consequence of vaccination against piroplasmosis. Berliner und Munchener Tierarztliche Wochenschrift 115(5-6): 167-172, 2002

Experimental transfusion reactions in monkeys: haemolytic, coagulant and renal effects of transfused isoimmune IgG and IgM. British Journal of Haematology 23(6): 765-776, 1972

Efficacy and safety of intravenous Ig and alterations in haematological parameters of infants with isoimmune haemolytic disease. Archives of Disease in Childhood. Fetal and Neonatal Edition 97(1): F76-F77, 2012

IgG subclasses and antibodies to group B streptococci in preterm neonates after intravenous infusion of immunoglobulin to the mothers. Pediatric Infectious Disease 5(3 Suppl): S195-S197, 1986